Company record
Scope Health Inc
1 FDA warning letter since 2023 and 1 recall in the last 12 months.
Get an email the day FDA posts anything new about Scope Health Inc.
Warning letters
-
DrugsScope Health Inc
FDA says Scope Health sold unapproved OTC eye drugs online and misbranded several products.
High risk
Recalls
| Reported | Class | Firm | Product and reason |
|---|---|---|---|
| May 6 | Class II | SCOPE HEALTH Drug |
Optase Dry Eye Intense Drops (Glycerin 0.2%), packaged in 0.33 fl oz, Sterile, Manufactured for Scope Health Inc., 79 Madison Ave., 8th Floor, New York, NY 10016, USA, NDC 72972-002-01. Lack of Assurance of Sterility |